帕羅西汀
帕羅西汀 (Paroxetine) 是一種強效的**選擇性血清素再攝取抑制劑 (SSRI)**,在獸醫學中常以仿單標示外使用 (off-label use) 的方式來進行行為修飾治療。 * **犬隻**:用於治療攻擊行為、刻板行為、強迫症 (OCD) 以及廣泛性焦慮症。 * **貓咪**:有助於改善尿液記號行為 (亂尿尿)、貓咪間的攻擊行為以及與焦慮相關的睡眠障礙。 > **臨床要點**:與氟西汀 (Fluoxetine) 相比,帕羅西汀的半衰期較短且無活性代謝物,若出現不良反應,其藥物清除期較短。然而,它具有輕微的抗膽鹼作用,因此便秘是較常見的副作用,特別是在貓咪身上。
作用機制: Paroxetine acts by selectively blocking the **serotonin transporter (SERT)** on the presynaptic neuronal membrane in the central nervous system. * Inhibition of **SERT** → Decreased reuptake of **serotonin (5-HT)** from the synaptic cleft → Increased concentration and prolonged activity of **5-HT** at postsynaptic **5-HT receptors**. * This potentiation of serotonergic neurotransmission helps regulate mood, anxiety, and compulsive behaviors. * Paroxetine has minimal affinity for **dopamine** or **norepinephrine** receptors, but does exhibit mild affinity for **muscarinic acetylcholine receptors**, contributing to its anticholinergic side effect profile.
各物種劑量
- SSRI responsive behavior problems · 0.5-1 mg/kg q24h (2.5-5 mg per cat q24h) · PO · q24h
- Compulsive disorders · 0.5-1 mg/kg PO once daily (q24h) · PO · q24h
- Generalized anxiety disorder · 0.5-1.5 mg/kg q24h · PO · q24h
- Marking · 0.5-1 mg/kg PO once daily · PO · q24h
- Intercat aggression · 0.5-1 mg/kg PO once daily · PO · q24h
- SSRI responsive behavior problems · 0.5-1.5 mg/kg PO q24-48h · PO · q24-48h
- Urine marking (especially with overt aggression) · 0.5-1 mg/kg · PO · q24h · Long-term as needed · Can be increased to 2 mg/kg PO q24h but close monitoring is required. Monitor urination frequency.
- Compulsive disorders · 1 mg/kg (up to 3 mg/kg) PO once daily (q24h) · PO · q24h
- Generalized anxiety disorder · 1-1.5 mg/kg q24h · PO · q24h
- Adjunctive treatment of phobias, fears, and anxieties · 0.5-1 mg/kg PO once daily · PO · q24h
- Generalized anxiety and impulsivity · 1-2 mg/kg · PO · q24h · Long-term as needed · Fluoxetine or clomipramine may be preferable due to authorized veterinary status.
給藥途徑
禁忌症
- Patients with known hypersensitivity to paroxetine
- Patients receiving monoamine oxidase inhibitors (MAOIs)
- Known hypersensitivity to paroxetine or other SSRIs
- History of seizures or epilepsy
- Concurrent use of Monoamine Oxidase Inhibitors (MAOIs)
- Concurrent use of other serotonergic agents (due to serotonin syndrome risk)
不良反應
- Anorexia (common, usually transient)
- Lethargy
- GI effects
- Anxiety
- Irritability
- Insomnia/hyperactivity
- Panting
- Aggressive behavior in previously unaggressive dogs
- Constipation (especially in cats)
- Changes in elimination patterns
- Changes in blood glucose levels
- Reduced seizure threshold
- Decreased appetite
- Vomiting
- Trembling
- Restlessness
- Gastrointestinal disturbance
藥物相互作用
- Buspirone · Increased risk for serotonin syndrome
- Cimetidine · May increase paroxetine levels
- Cyproheptadine · May decrease or reverse the effects of SSRIs
- Digoxin · Paroxetine (in humans) can decrease digoxin AUC by 15%
- Insulin · May alter insulin requirements
- Isoniazid · Increased risk for serotonin syndrome
- MAO Inhibitors (including amitraz and selegiline) · High risk for serotonin syndrome; use contraindicated. A 5-week washout period is required after discontinuing paroxetine, and a 2-week washout if discontinuing the MAOI first.
- Pentazocine · Serotonin syndrome-like adverse effects possible
- Phenobarbital · May decrease paroxetine levels
- Phenytoin · Increased plasma levels of phenytoin possible; may decrease paroxetine levels
- Propranolol, Metoprolol · Paroxetine may increase these beta-blockers' plasma levels and cause hypotension; atenolol may be safer
- Tramadol · SSRIs can inhibit the metabolism of tramadol to active metabolites, decreasing efficacy and increasing toxicity risk (serotonin syndrome, seizures)
監測
- Efficacy of behavioral modification
- Adverse effects (including appetite and weight changes)
- Behavioral changes (efficacy, paradoxical anxiety, or increased aggression)
- Frequency of urination (especially in cats)
- Signs of serotonin syndrome (tremors, agitation, hyperthermia)
- Gastrointestinal tolerance (appetite, vomiting)
過量
Experience with overdoses in humans yields a mixed picture; while not as toxic as tricyclic antidepressants, fatalities and significant morbidity have occurred. * **Clinical Signs**: ASPCA APCC data (2008-2009) reported common findings in dogs including **hyperactivity, lethargy, mydriasis, and trembling**. In cats, **mydriasis** was commonly noted. * **Treatment**: In small animal overdoses, err on the safe side. Employ **gut evacuation** (if not contraindicated) followed by supportive care. **Activated charcoal** is very effective in binding paroxetine. * **Serotonin Syndrome**: If serotonin syndrome develops, **phenothiazines** and **cyproheptadine** can be effective for control. Contact an animal poison control center for additional guidance.
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。